Applications and limitations in translating genomics to clinical practice

  • Brian Van Ness
    Reprint requests: Dr Brian Van Ness, 3-240 Cancer Center Research Building, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455
    Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minn
    Search for articles by this author
      Recent efforts to broadly apply genetics to clinical practice have been driven by the rapid advancement of genomic technologies and the discovery of genes associated with disease risk, progression, and treatment response. Yet there remain valid concerns about the complexities and limitations that confront the popular notion of clinical utility of genetics in personalized medicine. Research is still very much in the mode of discovery. The excitement of discovery and applications to diagnostics are well described in each of the articles in this issue. Yet, each article appropriately acknowledges the limitations that need to be overcome to apply new knowledge to clinical practice.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Weston A.D.
        • Hood L.
        Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine.
        J Proteome Res. 2004; 3: 179-196
      1. American Medical Association and Medco Health Solutions. 59th Annual American society of human genetics conference. 2013.

        • Venter J.C.
        • Adams M.D.
        • Myers P.W.
        • et al.
        The sequence of the human genome.
        Science. 2001; 291: 1304-1351
        • International Human Genome Sequencing Consortium
        Initial sequencing and analysis of the human genome.
        Nature. 2001; 409: 860-945
        • Corvol H.
        • Thompson K.
        • Tabary O.
        • Le Rouzic P.
        • Guillot L.
        Translating genetics of CF to personalized medicine.
        Transl Res. 2015; 168C: 40-49
        • Green R.C.
        • Berg J.S.
        • Grody W.W.
        • et al.
        ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
        Genet Med. 2013; 15: 565-574
        • Miles C.J.
        • Behr E.R.
        The role of genetic testing in unexplained sudden death.
        Transl Res. 2015; 168C: 59-73
        • Pouladi N.
        • Bime C.
        • Garcia J.G.N.
        • Lussier Y.A.
        Complex genetics of pulmonary disease: lessons from GWAS and next-generation sequencing.
        Transl Res. 2015; 168C: 22-39
        • Manolio T.A.
        • Collins F.S.
        • Cox N.J.
        • et al.
        Finding the missing heritability of complex diseases.
        Nature. 2009; 461: 747-753
        • Maher B.
        The case of the missing heritability.
        Nature. 2008; 456: 18-21
        • Flier J.S.
        • Mekalanos J.J.
        Gut check: testing the role for the intestinal microbiome in human obesity.
        Sci Transl Med. 2009; 1: 6-7
        • Parracho H.M.
        • Bingham M.O.
        • Gibsom G.R.
        • McCartney A.L.
        Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children.
        J Med Microbiol. 2005; 54: 987-991
        • Zhang F.
        • Wen Y.
        • Guo X.
        CRISPR/Cas9 for genome editing: progress, implications and challenges.
        Hum Mol Genet. 2014; 23: R40-R46
        • Baltimore D.
        • Berg P.
        • Botchan M.
        • et al.
        A prudent path forward for genomic engineering and germline gene modification.
        Science. 2015; 348: 36-38
      2. Available at: Accessed January 3, 2016.

      3. Available at: Accessed January 3, 2016.

      4. Food and Drug Administration. Anticipated details of the draft guidance for industry, Food and Drug Administration staff, and clinical laboratories: framework for regulatory oversight of laboratory developed tests (LDTs). 2014. Available at: Accessed January 3, 2016.

      5. Joyner MJ. ‘Moonshot’ medicine will let us down. New York Times. 2015. p A27.

        • Collins F.S.
        • Varmus H.
        A new initiative on precision medicine.
        N Engl J Med. 2015; 372: 793-795